$23.34
0.26% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Tyra Bioscience Stock price

$23.34
+1.68 7.76% 1M
+7.04 43.19% 6M
+9.49 68.52% YTD
+9.33 66.60% 1Y
+5.39 30.03% 3Y
-2.66 10.23% 5Y
-2.66 10.23% 10Y
NYSE, Closing price Fri, Sep 27 2024
-0.06 0.26%
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Key metrics

Market capitalization $1.23b
Enterprise Value $863.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.27
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-95.45m
Free Cash Flow (TTM) Free Cash Flow $-64.26m
Cash position $373.80m
EPS (TTM) EPS $-1.69
P/E forward negative
Short interest 8.15%
Show more

Is Tyra Bioscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Tyra Bioscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

Buy
86%
Hold
14%

Financial data from Tyra Bioscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.43 0.43
30% 30%
-
-0.43 -0.43
30% 30%
-
- Selling and Administrative Expenses 20 20
34% 34%
-
- Research and Development Expense 75 75
72% 72%
-
-95 -95
62% 62%
-
- Depreciation and Amortization 0.43 0.43
30% 30%
-
EBIT (Operating Income) EBIT -95 -95
62% 62%
-
Net Profit -81 -81
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tyra Bioscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tyra Bioscience Stock News

Neutral
PRNewsWire
17 days ago
CARLSBAD, Calif. , Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024 Cantor Global Healthcare Conference.
Neutral
PRNewsWire
18 days ago
-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif. , Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that ta...
Neutral
Accesswire
about one month ago
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
More Tyra Bioscience News

Company Profile

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Head office United States
CEO Todd Harris
Employees 49
Founded 2018
Website www.tyra.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today